Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has announced the conversion of NOK 2,500,000 worth of convertible bonds into 4,166,666 new shares, increasing its share capital to NOK 59,345,650.20. This move, involving Atlas Special Opportunities, LLC, aligns with Circio’s strategic financial operations and strengthens its market position in the biotechnology sector.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced circular RNA vector expression technology for nucleic acid medicine. The company has created a unique circRNA vector expression platform, circVec, which enhances protein expression and durability compared to traditional mRNA systems. Circio is also working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,319,826
Current Market Cap: NOK59.69M
For a thorough assessment of 0RIS stock, go to TipRanks’ Stock Analysis page.